Afinitor is now approved to treat unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) NET of GI or lung origin in adults with progressive disease. The approval
Ireland-based Jazz will pay $30.25 per share in cash for Celator and get access to Vyxeos, an investigational product in development to treat acute myeloid leukemia (AML). The
It expands the initial EC approval in October 2014 for several patients with CLL. Imbruvica is now available to treat all lines of CLL in the European Union
The milestone payment was triggered by the initial commercial sale of Darzalex in Europe. Earlier this month, the European Commission granted conditional approval to Darzalex to treat adults
The patient will be treated at University Hospital Germans Trias i Pujol in Badalona, Barcelona, Spain. Abivax will undertake the trial at clinical centers in Spain and Belgium,
Flixabi is now approved to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Flixabi demonstrated comparable safety and equivalent efficacy to Remicade in
Children born with ADA-SCID do not have a fully functioning immune system and are unable to fight off common infections. The disease affects nearly 15 children a year
The study compared Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) to treat locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for
Zinbryta is a humanized IgG1 monoclonal antibody that selectively binds to the high-affinity interleukin-2 (IL-2) receptor subunit (CD25), a protein that is over-expressed on T cells that become
SYM-1219 is a potent, next-generation 5-nitroimidazole antibiotic intended for single-dose oral treatment of BV. Symbiomix also announced a successful meeting with the US Food & Drug Administration (FDA)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.